Unlocking Hope: PaxMedica's Mission to Tackle Autism

PaxMedica's CEO discusses rising autism rates, PAX-101 breakthrough, & mission to develop treatments. Join our journey.
  • Autism Spectrum Disorder (ASD) has seen a staggering fourfold increase in the United States over the past two decades.
  • PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism.
  • Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials.
  • In 2024, we're poised to submit a New Drug Application (NDA) for PAX-101 to treat Human African Trypanosomiasis (HAT), a rare disease also known as African Sleeping Sickness, as part of the Neglected Rare Tropical Disease Program.
  • With NDA approval, we anticipate the potential to secure a valuable Priority Review Voucher (PRV) that could expedite our journey toward FDA recognition for Autism treatment.
  • Vigorous preparations are underway for clinical trials of PAX-101 in Autism, marking a significant step forward in our mission.